Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans. - Wikidata - wikimedia - TriplyDB

Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans.

Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans.

http://www.wikidata.org/entity/Q37153223

about

Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1 Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes Association between blood glucose variability and coronary plaque instability in patients with acute coronary syndromes.Interleukin-6 predicts inflammation-induced increase of Glucagon-like peptide-1 in humans in response to cardiac surgery with association to parameters of glucose metabolism Twenty-four-week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus.Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies.Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients.Exendin-4 ameliorates cardiac ischemia/reperfusion injury via caveolae and caveolins-3.Circulating levels of apelin, glucagon-like peptide and visfatin in hypercholesterolemic-hyperhomocysteinemic guinea-pigs: their relation with NO metabolism.Exendin-4 promotes endothelial barrier enhancement via PKA- and Epac1-dependent Rac1 activation.Reduced post-operative DPP4 activity associated with worse patient outcome after cardiac surgery

P2860

Q26752511-56DB0398-C8C7-4D12-B2E3-0CC15E9DD8A0 Q26823085-C57AD240-5503-45A5-BEF2-67FC36DDB3FC Q34994502-943669A1-016A-4F9E-B5A6-302A56B1011D Q35986383-CAE6E5A3-A95B-4323-8288-039B6DE4FF3A Q36538532-AAC7DBFF-ADCE-4481-92A7-2346BA28F77E Q36757419-0C29042B-3383-4814-B98F-AEF2E070DFCB Q37402790-1D2EBFA6-50E7-44DB-B4C5-B63E9F4B2C2F Q37581317-3FD09049-D2E4-4EE3-8269-E058837D36A3 Q41852482-59759B33-FCBC-45CA-BF67-42797BC81832 Q46379488-FB129A09-9627-4A7C-8A3F-438BCF7B37A4 Q54311139-E2207FB5-D97C-40DA-B3D3-73CC9C32C7E3 Q58797884-2F189487-33BD-4F26-B25C-A6E0A7B23064

P2860

Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans.

http://www.wikidata.org/entity/Q37153223

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 16 August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Circulating concentrations of ...... ary atherosclerosis in humans.

@en

Circulating concentrations of ...... ary atherosclerosis in humans.

@nl

type

label

Circulating concentrations of ...... ary atherosclerosis in humans.

@en

Circulating concentrations of ...... ary atherosclerosis in humans.

@nl

prefLabel

Circulating concentrations of ...... ary atherosclerosis in humans.

@en

Circulating concentrations of ...... ary atherosclerosis in humans.

@nl

P1433

Q37153223-3B46F7F3-7B5B-4AA5-B1EE-71F41706FDE0

P1476

Q37153223-89C9A3A6-4EFE-4D83-AA85-9BFC60AEA50C

P2093

Q37153223-1294E23A-5302-4A62-A70D-14B1A9D2300D

Q37153223-1592EAFA-C72E-446F-9ACD-FB1EA41489A8

Q37153223-1DE7AADB-5B65-4EBA-99F1-F74395BAE64B

Q37153223-217B1B5C-261B-49F6-9DCC-42F6279D2E00

Q37153223-257800D5-A9C4-41DE-8525-82F51A1B766D

Q37153223-51B3BD77-1692-4DD2-89B9-1A800AC96FA1

Q37153223-59141A95-27C2-4726-9C8E-B41DC05953EB

Q37153223-5DAA4D92-C9E6-4394-BAC5-F63532AD0C8B

Q37153223-79BECAD6-B4B9-4B80-9624-DE733C0C9A2F

Q37153223-9A638AC0-5946-4C38-A73E-182B098E69D1

P2860

Q37153223-03B27AB0-F768-44E6-A5AC-6DDCBF8BC69F

Q37153223-1573C80C-7D37-493E-8653-59E2BAAE8F11

Q37153223-1EA25FBC-C6F2-4A97-B722-C5B5AAE4C74C

Q37153223-210C7C44-6FEA-42DF-9ED7-46B84F50554B

Q37153223-43E461A7-7637-49FE-9699-4B8BA5C187C7

Q37153223-46FCD397-7FE9-490E-999B-BC68720769FE

Q37153223-50B1B324-4F74-42AF-953C-4811366F9607

Q37153223-514C3C07-1F56-45BA-8D24-5B6CA267CE86

Q37153223-7D739526-8DCE-408F-81D3-74513F17049C

Q37153223-8272DC03-87BB-4DE5-BFC8-266211BD2C48

P2888

Q37153223-668CF021-767D-46E6-8D99-6AA658921DAA

P304

Q37153223-36F753BF-7117-4D5F-9D54-223508B52D00

P31

Q37153223-C3F3D75B-DF3E-4B13-9E9E-D1DB37C34692

P356

Q37153223-59AEFE21-C155-436A-8C29-5DA40D83394A

P407

Q37153223-17F3C664-867E-444B-B47B-B6662B4DD576

P478

Q37153223-3D8FA40F-32E6-44D6-AA98-DF2BFD86B425

P577

Q37153223-8A042804-6A07-456C-A54B-6E8B9D65F7D4

P5875

Q37153223-6F17374C-21DB-4EEC-B820-0C664DB98CB3

P6179

Q37153223-B06D107B-EF0C-4A03-8E5D-0AB1BA3C7D78

P698

Q37153223-98BE90D0-F9C2-4248-9DB0-169B45F43EE5

P921

Q37153223-222758A2-1F73-4B76-AD37-5868D9DC716E

P932

Q37153223-333D5B73-D468-45F9-A9D4-2F8125E2D171

P356

1475-2840-12-117

P1433

Cardiovascular Diabetology

P1476

Circulating concentrations of ...... ary atherosclerosis in humans.

@en

P2093

Alexander Becker

http://www.w3.org/2001/XMLSchema#string

Alexander W Leber

http://www.w3.org/2001/XMLSchema#string

Burkhard Goeke

http://www.w3.org/2001/XMLSchema#string

Corinna Lebherz

http://www.w3.org/2001/XMLSchema#string

Gerald Spoettl

http://www.w3.org/2001/XMLSchema#string

Ingeborg Biller-Friedmann

http://www.w3.org/2001/XMLSchema#string

Julia Zugwurst

http://www.w3.org/2001/XMLSchema#string

Katja Piotrowski

http://www.w3.org/2001/XMLSchema#string

Klaus G Parhofer

http://www.w3.org/2001/XMLSchema#string

Martin Greif

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials

Biology of incretins: GLP-1 and GIP

HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study.

Low adiponectin levels are an independent predictor of mixed and non-calcified coronary atherosclerotic plaques

Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease

Diabetes mellitus, fasting glucose, and risk of cause-specific death.

Attenuated GLP-1 secretion in obesity: cause or consequence?

Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells.

Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial.

Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes.

P2888

1475-2840-12-117

P304

117

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1475-2840-12-117

http://www.w3.org/2001/XMLSchema#string

P407

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

255973881

http://www.w3.org/2001/XMLSchema#string

P6179

1044981529

http://www.w3.org/2001/XMLSchema#string

P698

23953602

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

3765863

http://www.w3.org/2001/XMLSchema#string